Inside the research

Danaher Corporation

DHR Research profile · latest available data

Price overview

$224.49

▲ +0.72 (+0.3%)

52w hi$241.04
52w lo$161.57
Vol4.42M
As of25 Sep 2026

The Verdict

Hold

Our score +0.21

Short+0.12
Medium+0.29
Long+0.26

computed 2026-09-27

Key fundamentals

Danaher Corporation

Healthcare · Diagnostics & Research

Market cap$157.81B
Enterprise value$181.33B
Trailing P/E40.02x
Forward P/E24.14x
EV / EBITDA22.59x
P / S (ttm)6.29x
Profit margin15.9%
Return on equity7.6%
Revenue growth+5.5%
Earnings growth+59.7%
Debt / equity52.97

Layer Breakdown

LayerRawContribution
Fundamental+0.24
Sector+0.08
Technical+0.02
Earnings+0.00
Sentiment+0.14

macro × 1.00 · 2026-09-27

Business overview

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

United States · www.danaher.com

Risk Metrics

Beta vs SPX0.79
Corr SPX0.41
Annual vol31.2%
Annual ret-4.8%
Sharpe-0.16
Max DD-41.8%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$250.14
High / Low$310.00 / $205.00
Median$247.50
Analysts22
Strong Buy3
Buy19
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-04-23Morgan Stanley→ Overweight
2026-04-22Wells Fargo→ Equal-Weight
2026-04-22UBS→ Buy
2026-04-22Guggenheim→ Buy
2026-04-22Baird→ Outperform
2026-04-17Baird→ Outperform

Officers & Board

FounderMitchell Rales current
ManagerSteven Rales current
FounderSteven Rales current

Material Events

DateEvent8-K
2026-08-03Officer / Director Change, Reg FD Disclosure…read
2026-07-21Earnings Release, Exhibitsread
2026-06-03Material Obligation, Other Material Eventread
2026-05-07Officer / Director Change, Shareholder Vote…read
2026-04-29Material Agreement, Other Material Event…read
2026-04-21Earnings Release, Exhibitsread
2026-04-17Material Agreement, Material Obligation…read
2026-02-17Other Material Event, Exhibitsread
2026-02-10Officer / Director Change, Exhibitsread
2026-01-28Earnings Release, Exhibitsread
2026-01-12Earnings Release, Exhibitsread
2025-11-06Officer / Director Change, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-04Gutierrez-Ramos Jose-CarlosSVP, Chief Science OfficeGrant13.48K—
2026-08-04Riley Christopher PaulExecutive Vice PresidentGrant41.07K—
2026-08-04Milosevich Gregory MExecutive Vice PresidentGrant15.40K—
2026-05-01SPOON ALAN GOption exercise3.30K$237.06K
2026-05-01SPOON ALAN GSell1.36K$237.21K
2026-03-01Milosevich Gregory MExecutive Vice PresidentWithheld for tax118$24.86K
2026-03-01Bouda ChristopherVP, Chief Accounting OffiGrant1.25K—
2026-03-01Bouda ChristopherVP, Chief Accounting OffiWithheld for tax170$35.81K
2026-03-01Gutierrez-Ramos Jose-CarlosSVP, Chief Science OfficeGrant6.65K—
2026-03-01Gutierrez-Ramos Jose-CarlosSVP, Chief Science OfficeWithheld for tax284$59.82K

Flow & Concentration

Insider 180d net-$237.21K
Insider buys / sells0 / 1
Insider biasNeutral
13F holders8
Top-5 share98.4%
HHI3,684 (concentrated)

Top Holders

HolderValueShares
Vanguard Group Inc$13.96B60.98M
State Street Corp$6.35B27.68M
Fidelity / FMR LLC$4.47B19.51M
Citadel Advisors$625.03M2.73M
Millennium Management$531.72M2.32M
AQR Capital Management$415.55M1.82M
Bridgewater Associates$7.26M31.72K
T. Rowe Price Group$3.66M15.97M

As of 2025-12-31

Dividends

Yield (TTM)0.32%
$ / share (TTM)$0.72
5y CAGR+14.9%

Annual dividend per share

2021$0.74
2022$0.89
2023$0.99
2024$1.08
2025$1.28
2026$0.40

Federal Contracts

AmountAgencyDescription
$146.27MDepartment of Veterans AffairsCOVID 19 FLU TEST KITS AND SWABS
$74.98MDepartment of Health and Human ServicesOTA - PANDEMIC PREPAREDNESS AND RESPONSE: ESTABLISHING A PLATFORM FOR DIAGNOSIS
$72.10MDepartment of Health and Human ServicesOTHER TRANSACTION AGREEMENT: CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUP
$59.69MDepartment of DefenseCOVID-19 DHHS INDUSTRIAL BASE EXPANSION FOR TEST KITS.
$37.83MDepartment of DefenseCOVID TESTS, DIAGNOSTIC SYSTEMS AND SERVICE AGREEMENTS.
$13.39MDepartment of Health and Human ServicesAB SCIEX SERVICE & MAINTENANCE AGREEMENT SUPPORT
$13.01MDepartment of Health and Human ServicesIGF::OT::IGFC103555 - (WATER TREATMENT)-REQUIREMENTS OUTLINED IN SOWLEO ANGELO G
$9.33MDepartment of Veterans AffairsMOLECULAR DIAGNOSTIC TESTS FOR SARS-COV-2

SEC Filings

DateFormDoc
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-064view
2026-08-044view
2026-08-044view
2026-08-044view
2026-08-044view
2026-08-044view
2026-08-044view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$23.88B+4.0%
Gross profit$14.03B+16.1%
Operating income$4.86B+6.6%
Net income$3.61B+6.5%
Cash from ops$6.69B+8.3%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$223.37$224.90$221.60$224.494.42M
Sep 24$220.50$226.65$219.00$223.776.20M
Sep 23$221.27$223.42$219.92$221.563.40M
Sep 22$215.10$222.42$214.28$221.094.63M
Sep 21$212.03$216.19$209.60$215.845.16M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →